Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
Study Number: 

PH 279015

Phase: 
III
Trial categories: 
Colorectal
Immunotherapy
Antibody therapy
Checkpoint blockade
Principal Investigator: